Actively Recruiting
Promoting Safe and Precise Hydroxyurea Dosing for Children with Sickle Cell Anemia in Sub-Saharan Africa
Led by Brown University · Updated on 2026-08-20
400
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Sickle cell anemia SCA is a severe blood disorder affecting over 300,000 newborns annually, mainly in sub-Saharan Africa where many children die early due to lack of diagnosis and care. This trial evaluates hydroxyurea, a daily oral medication used safely in high-resource settings, now being studied with a new precision dosing approach to improve safety and effectiveness in African children with SCA. The study is a randomized clinical trial aiming to develop evidence-based dosing and monitoring guidelines for hydroxyurea in this region. Participants will receive hydroxyurea either at a standard weight-based dose or an individualized dose guided by pharmacokinetics using a battery-powered machine and automated algorithm. This approach includes limited laboratory monitoring to make treatment more accessible in low-resource settings. The study involves 400 children with SCA in Luanda, Angola, comparing these two dosing strategies. During the trial, children will be monitored for clinical adverse events and laboratory responses over approximately 24 months. Researchers will assess the rate of serious sickle cell complications and other adverse events, alongside blood responses at 12 months. The study involves regular evaluations to ensure safety and gather data on the best dosing and monitoring practices, aiming to support widespread hydroxyurea use across sub-Saharan Africa.
CONDITIONS
Brief Title
Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa
Research Team
B
BrUOG
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here